Setmelanotide-mediated MC4R activation improves hypothalamic obesity via CaMKK2/AMPK pathways

Hypothalamic obesity (HO) is a disabling disease caused by central nervous system (CNS) damage due to neurosurgery, trauma, or tumors, especially in hypothalamus. The pathological mechanism of its neural circuits is still unclear, and there is currently no corresponding drug due to the complex etiol...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Junjie Peng, Yichao Ou, Mingfeng Zhou, Xingqin Wang, Xi’an Zhang, Hao Long, Guangsen Wu, Mengjie Che, Kai Li, Le Yang, Zhu Zhang, Ken Kin Lam Yung, Songtao Qi, Zhanpeng Feng
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Frontiers Media S.A. 2026-01-01
Saila:	Frontiers in Pharmacology
Gaiak:	CaMKK2/AMPK signaling GPCRs hypothalamic obesity melanocortin 4 receptor neuropharmacology setmelanotide
Sarrera elektronikoa:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1730786/full
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!